Myeloid Therapeutics is pioneering next-generation immunotherapies by harnessing the innate abilities of myeloid cells to combat cancer. Their innovative in vivo engineering platform specifically targets and activates these cells within solid tumors, facilitating a broader anti-tumor adaptive immune response without the need for ex-vivo cell manipulation. This approach utilizes lipid nanoparticles (LNPs) encapsulating mRNA, which are selectively taken up by myeloid cells, leading to effective tumor cell destruction across various cancer models. Their lead product, MT-302, is designed to target TROP2, a tumor-associated antigen prevalent in epithelial tumors, demonstrating significant therapeutic potential even in the absence of T cells.

Additionally, Myeloid Therapeutics is advancing gene-editing technologies through their RetroT™ platform, which employs retrotransposon-mediated gene insertion. This method allows for the delivery of larger genetic sequences into the genome compared to existing technologies, enabling the correction of genetic errors in situ. Their second clinical candidate, MT-303, targets hepatocellular carcinoma (HCC) and showcases the ability of programmed myeloid cells to elicit a full immune response by presenting tumor neoantigens to stimulate T cells. Collectively, these technologies position Myeloid Therapeutics at the forefront of cancer treatment, focusing on enhancing the immune system's natural capabilities to fight malignancies.

United States

At Myeloid, we have applied our extensive knowledge of advanced gene and cell therapies to build novel platform technologies that harness the innate abilities of myeloid cells. We have translated the learnings from our backgrounds and novel platform to create a clinical-stage, mRNA-immunotherapy pipeline focused on breakthrough therapies for cancer.

Myeloid Therapeutics

Company Details